RNA: Philly drug developer Aro to get $1.4 billion if it meets Ionis’ targets

U City start-up Aro Biotherapeutics sets targets to deliver RNA drugs

RNA: Philly drug developer Aro to get $1.4 billion if it meets Ionis’ targets

U City start-up Aro Biotherapeutics sets targets to deliver RNA drugs

Reading the tea leaves: What 10 cannabis bigwigs predict 2020 will bring to the world of weed

In Pennsylvania, you’ll see more supply coming to the market in 2020. Meanwhile a referendum in New Jersey could accelerate the push to legalization.

Reading the tea leaves: What 10 cannabis bigwigs predict 2020 will bring to the world of weed

In Pennsylvania, you’ll see more supply coming to the market in 2020. Meanwhile a referendum in New Jersey could accelerate the push to legalization.

Genetic test at Acme pharmacies guides choice of psychiatric medications

The test, which is evaluated by a King of Prussia company and requires a prescription, is available at all 37 ACME pharmacies in southeastern Pennsylvania,

Genetic test at Acme pharmacies guides choice of psychiatric medications

The test, which is evaluated by a King of Prussia company and requires a prescription, is available at all 37 ACME pharmacies in southeastern Pennsylvania,
More Stories

THC vape dealers are stealing customers’ money online, FDA says

If you must vape, buy from a state-regulated dispensary.

Column

Cell Factory Town: Philly docs expect Roche-Spark deal will draw billions ($$$) and thousands (jobs) to new gene labs here

Roche's " vision is very much, long-term oriented, to make Philadelphia the center of excellence for gene therapy within the Roche group” under the Spark name, said Spark CEO Jeffrey Marrazzo

Sackler family transferred $1.36 billion in Purdue Pharma profits overseas, company says in court filing

The bankruptcy court filing discloses more than $10 billion transferred out of the OxyContin manufacturer.

N.J. voters to decide on legalizing marijuana

Super-majorities in the state Senate and Assembly approved putting a question on the November 2020 ballot.

PhillyBioCapital: Humana buys Philly-based Enclara; NeuroFlow raises $7.5 million

Enclara will be part of health insurance giant; Neuroflow, with VC backing, plans hires.

The cannabis biz is down, but long term it’s smoking, analysts say, as marijuana industry gathers in Las Vegas

“You know you’re at the bottom when Willie Nelson stops smoking weed,” quipped one equity analyst. Nelson, 86, a music legend and marijuana advocate, announced last week he was giving up his daily joints. The industry still has many growth prospects.

Antibiotics firms struggle to make money despite cries for new drugs. Is the market broken?

Firms that have gotten approval for new antibiotics lately have found themselves in dire financial straits.

‘Like a traveler on the Oregon Trail’: Katherine High on making gene therapy a viable option | Industry Icons

Kathy High was at the epicenter of creating gene therapy, "and she has put Philadelphia at that epicenter,” one expert said.

PhillyBioCapital: $80M for Impulse heart pumps; LLR gives Relay $30M to text more

South Jersey-based Impulse Dynamics plans to take its FDA-approved, improved heartbeat assistance system to market

King of Prussia offers more than high fashion: Its 3rd medical marijuana shop opens next week

The new dispensary, in a former mattress showroom on the Dekalb Pike, will hold an open house on Saturday.

AdaptHealth follows $30M McKesson deal with Advanced pact; Roche-Spark nears deadline

AdaptHealth buys McKesson unit for $30M; Spark-Roche deal held til December

Biotech IPO frenzy brings some Philly firms into the stock market before they sell products or earn profits

That's risky, but going public gives fledgling companies a way to boost clients, sales and profits.

SPECIAL REPORTS
Investigative reports, featured series, and guides to living in the Philadelphia region, brought to you by The Inquirer.
WHAT ARE YOU CURIOUS 7073彩票登录?
Send us your burning questions, or vote on other readers' questions that pique your interest. Our journalists will work to answer them.